Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib, Dasatinib and Prednisone in Older Patients with Ph+ ALL
NCT02815059Phase 1Withdrawn
- Sponsor
- University of Utah
- Start
- Sep 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrutinib in acute lymphoblastic leukemia (ALL), sponsored by University of Utah. Primary endpoint: Incidence of adverse events of combination of ibrutinib and dasatinib at 90 days. Planned start Sep 2016; status: withdrawn.
02
Drugs
ibrutinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02815059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02815059.